1. Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

2. Introduction

3. Residual Ischemic Risk in Patients With Previous MI and Without Prior Stroke or TIA

4. Outcomes Among Survivors After Acute MI: Real-World Data From the APOLLO Registry

5. Duration of DAPT in Medically Treated Patients With ACS

6. Clopidogrel Plus ASA vs ASA Alone for the Prevention of Atherothrombotic Events

7. DAPT After Drug-Eluting Stents: Results of the DAPT Trial

8. DAPT After PCI in Patients With and Without Acute MI: Results From the DAPT Trial

9. PEGASUS-TIMI 54 Trial Design

10. PEGASUS-TIMI 54: Key Inclusion and Exclusion Criteria

11. PEGASUS-TIMI 54 Trial Design (cont)

12. PEGASUS-TIMI 54 Primary Endpoint: Rate of CV Death, MI, or Stroke

13. PEGASUS-TIMI 54: Components of the Primary Endpoint

14. PEGASUS-TIMI 54 Safety: Bleeding

15. Ticagrelor in Patients With Prior MI in the Approved European Label: Data From PEGASUS

16. Ischemic and Bleeding Outcomes in Patients With Prior MI in the Approved European Label

17. COMPASS Trial Design

18. COMPASS Results: Rivaroxaban With or Without ASA in Stable CVD

19. Putting It All Together: What Do the Data Tell Us?

20. Putting It All Together: What Do the Data Tell Us? (cont)

21. Candidates for Long-Term DAPT Post-MI

22. How Long Should Long-Term DAPT Be Continued Post-MI?

23. Summary and Conclusions

24. Abbreviations

25. Abbreviations (cont)